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Summary (Dbersetzung siehe Karteikarte) 
Malignant lymphomas developed in 9 renal homograft recipients treated at widely 
separated transplantation centers. The development of these tumors appears to be an 
indirect complication of organ transplantation and/or the measures taken to prevent 
rejection. A further complication may be an increased incidence of epithelial tumors. 
It also seems likely that immune paralysis may accelerate the growth of metastases. 
In our experience with a large s·eries of renal 
transplantation patients who survived at least 
6 months and were followed for periods as long 
as 6 years or more there has been approximately 
a 3 percent incidence of malignant tumors, par-
ticularly lymphomas [40]. In 1968 we reported 
[33] 5 cases of this type of tumor which occurred 
at 3 widely separated transplant centers. One 
of these cases was subsequently extensively 
restudied and was reclassified as an un-
differented carcinoma [23]. Since then further 
cases have been described from several other 
transplant centers. At the present time there 
are 9 cases of lymphomas which developed in 
the more than 2,500 known renal homotrans-
plant recipients. 
Clinical Material 
The salient features of these cases are sum-
marized in Tables 1 and 2. 
Case 1 (Denver) [33] 
Before the transplant operation in May 1967 
the patient complained of headaches, dizziness, 
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blurred vision, nausea and vomiting. He also 
had two generalized epileptiform seizures. 
Neurologic examination was negative and his 
symptoms were attributed to severe hyper-
tension. 
Two months after the transplant operation he 
had a generalized seizure and was confused and 
incoherent for several days. At that time he had 
threatened rejection of the homograft, was 
hypertensive, and was found to be exceeding 
his restricted fluid allowance. Serum chemistries 
showed marked hemodilution. A diagnosis of 
wateT intoxication was made. This condition 
promptly improved with treatment consisting 
of fluid restriction and administration of so-
dium chloride and potassium supplements. No 
further neurologic symptoms occurred until 
9 days before a diagnosis of reticulum cell 
sarcoma was made by craniotomy. This very 
extensive tumor of the brain caused the 
patient's death. Renal function was normal in 
the last months of life. 
In this case, the possibility could not be ex-
cluded that the tumor was present at the time 
of transplantation and was the cause of his 
earlier neurologic symptoms. 
Case 2 (Denver) [33] 
In addition to the immunosuppressive agents 
mentioned in Table 1 the patient was treated 
with Actinomycin C and local homograft ir-
radiation to control threatened rejection. After 
his transplant operation he had persistent 
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Table 1. Lymphomas in Renal Transplant Recipients. 
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t: 
o 
I) 
Immunosuppression 
1 Denver 14 M Mother Yes No Yes Yes Yes Relic. Cen 
Sarcoma 
51/2 
months 
Brain Fatal 
2 Denver 23 M Father Yes Yes Yes Yes No Relic. Cen 
Sarcoma 
30 
months 
Thyroid; Liver 
Lung; Stomach; 
Prostate; 
PituitarYi 
Fatal 
Skin; 
3 Denver 20 F Father Yes No Yes Yes Yes Possible 
Plasma-
7 
months 
Psoas Muscle 
Brain Alive 
cytoma 
4 Edinburgh, 26 F Mother No No Yes Yes Yes*' Relic. Cell 241/. 
months 
Mediastinal 
lymph nodes; 
Pleura 
Buttock 
Fatal 
Scotland Sarcoma 
5 Cleveland 32 M Cadaver No No Yes Yes Yes Retic. Cen 
Sarcoma 
22 
months 
Alive 
6 New York 35 F Cadaver No No Yes Yes No Visceral 10 
months 
Lungs; 
Esophagus; 
Stomach; 
Fatal 
7 Richmond 35 M Cadaver No No Yes Yes 
8 Auckland, 34 M Cadaver No No Yes Yes 
New 
Zealand 
9 Auckland, 46 F Cadaver No No Yes Yes 
New 
Zealand 
* A variety of lymphoma [31, 32] . 
•• ALG Treatment post-dated for sl evidence of the neoplasm. 
hypercalcemia which necessitated a para-
thyroidectomy on March 29, 1966. The thyroid 
gland was normal at this operation; but at 
autopsy on December 6, 1967 it was found to 
be enlarged and almost completely replaced by 
tumor. Up till the time of death renal function 
had been subnormal, but adequate. 
Death occurred 6 days after emergency vago-
tomy and partial gastrectomy performed to 
control massive upper gastro-intestinal bleed-
ing, The resected portion of stomach contained 
several ulcers; in the bases of which were small 
collections of tumor cells closely resembling 
those found in the brain in Case 1. At autopsy 
widespread tumor was found (Table 1). 
Case 3 (Denver) [33] 
In the early part of her post-transplant course 
threatened rejection required treatment with 
Actinomycin C and local homograft irradiation. 
Seven months after renal homotransplantation 
she developed a rapidly progressing left hemi-
paresis, A lesion in the right anterior and mid-
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No 
No 
No 
Kaposi's 
Sarcorna* 
Retic. Cen 
Sarcoma 
Retic. Cen 
Sarcoma 
Relic. Cen 
Sarcoma 
Urinary 
bladder; 
Mediastinal 
and abdominal 
lymph nodes. 
31 
months 
Lung Fatal 
7 Tongue; Fatal 
months Esophagus; 
Liver 
9 Brain Fatal 
months 
thalamic areas was identified with pneumo-
encephalography and hiopsied with a stereo-
taxic technique. The histologic findings were 
consistent with a tumor of lymphoid origin, 
possibly a plasmacytoma. Further studies re-
vealed no evidence of tumor elsewhere in the 
body and no evidence of multiple myeloma. 
Reduc.tion in the dosage of prednisone and 
azathioprine combined with radiotherapy to the 
brain resulted in striking improvement in the 
patient's neurologic condition. At present, more 
than a year since the tumor was treated she is 
in good health apart from a moderate degree of 
residual hemiparesis. 
Case 4 (Edinburgh) [45] 
Several rejection episodes required increase of 
prednisone dosage. Later, ALG was used in an 
attempt to reduce the amount of steroid therapy. 
Right sided pleurisy developed 518 days after 
renal homotransplantation, A loculated effusion 
between the right upper lobe and mediastinum 
was seen in a radiograph of the chest. This 
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slowly diminished in size when antibiotics were 
given and could no longer be seen 21/2 months 
later. A chest x-ray 725 days post-transplanta-
tion showed recurrence and extension of 
the aforementioned radiographic abnormalities. 
Operation rE'vealed a rE'ticulum cell sarcoma of 
the mediastinal lymph nodes and pleura. The 
patient died 760 days after transplantation. 
The kidney functioned throughout life. 
Case 5 (Cleveland) [17] 
The donor was a 7 year old girl who died fol-
lowing surgery for a medulloblastoma. Seven 
months after transplantation the patient was 
treated for threatened rejection of the kidney 
with intravenous Actinomycin C,local Cobalt 60 
to the graft site and with 37 intramuscular in-
jections of ALG, in addition to maintenance 
therapy with Imuran and prednisone. The ALG 
injections were administered over a period of 
8 weeks, and were placed in the buttocks. Ap-
proximately 6 weeks after the first ALG in-
jection the patient noted a small nodule in the 
left buttock at the site of an ALG injection. The 
mass persisted unchanged for 10 months and 
then started to enlarge. It was then widely ex-
cised and the residual defect was skin grafted. 
Histologic examination of the mass revealed a 
typical reticulum cell sarcoma. 
Immunofluorescent techniques failed to show 
any horse gamma globulin in the tumor. Elec-
tron microscopy failed to show any virus par-
ticles. 
Renal function has remained satisfactory up to 
the present time. The patient remains well but 
lymphangiography shows possible involvement 
of the aortic nodes by metastatic tumor. 
Casc 6 (Albert Einstein College of Medicinc, 
New York) [38] 
The transplant was from a cadaver donor who 
had no evidence of malignant disease. Several 
Table 2. Lymphomas In Renal Transplant Recipients. 
Organ 
Brain 
Lung 
Skeletal Muscle 
Liver 
Esophagus 
Stomach 
Lymph Nodes 
Organs Mainly Affected 
Number of Patients 
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months following transplantation there were 
several episodes of threatened rejection which 
required treatment with Actinomycin C and 
local radiotherapy, as well as adjustment of the 
doses of azathioprine and prednisone. These 
episodes left the patient with impaired renal 
function. Seven months post-transplantation a 
right lower lobe infiltrate developed. This re-
solved with antibiotic therapy, but the patient 
was left with a cavitary lesion which persisted 
till her death 10 months post-transplantation. 
Autopsy showed a chronic lung abscess and bi-
lateral bronchopneumonia; evidence of pro-
gressive rejection in the transplanted kidney; 
and a widely disseminated tumor with the histo-
logic features of the visceral form of Kaposi's 
sarcoma. 
Case 7 (Richmond) [34] 
Several rejection episodes required treatment 
with Actinomycin C in addition to routine ther-
apy with azathioprine, prednisone and local 
irradiation of the kidney. Dyspnea and ascites 
developed 27 months follOWing transplantation 
and he was treated for pneumonia, pulmonary 
insufficiency and congestive heart failure. Four 
months later a chest x-ray showed a nodule in 
the right lower lung field. Four days later the 
patient died of a cerebral hemorrhage. At 
autopsy there were two nodules in the right 
lower lobe which histologically were reticulum 
cell sarcoma. 
There was no evidence of involvement of other 
organs. 
Case 8 (Auckland, New Zealand) [18] 
Four mild episodes of transplant rejection with 
temporary decline in renal function were treated 
with high doses of prednisone and with Actino-
mycin C. Thereafter renal function remained 
satisfactory till his death. 
Five months following transplantation he de-
veloped extensive herpetic lesions on the lips 
and inside his mouth. Candida albicans was 
cultured from the oral swab. Despite appropri-
ate therapy the tongue became ulcerated, the 
oral lesion spread to involve the esophagus and 
marked cervical adenopathy developed. His 
condition steadily deteriorated and he died. At 
autopsy there was severe ulceration of the lips, 
the right side of the face, both eyelids, the 
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tongue and the lower two thirds of the esoph-
agus. Deep to the ulcers of the tongue and 
esophagus were areas of reticulum cell sarcoma. 
In addition, there were nodules of this tumor in 
the liver. 
Case 9 (Auclcland, New Zealand) [181 
During the first 3 months after transplantation 
the patients had three easily reversible episodes 
of decreased renal function. Three months after 
transplantation she developed severe labial her-
pes simplex infection, which spread to involve 
the nose. The labial lesions healed after 2 
months, but the nasal lesions progressed and 
led to destructive rhinitis with septal per-
foration, which was still present at the time of 
death. For the month before death she was 
severely toxic with systemic staphylococcal in-
fection, including a lung abscess. 
At autopsy a reticulum cell sarcoma was found 
close to the surface of the right parietal cortex. 
Discussion 
Animal studies have shown that malignant 
tumors may develop in certain conditions 
characterized by disturbances of the host's im-
mune defenses [361. In man the same appears 
to be true. For example, patients with agamma-
globulinemia and deficiences of cell mediated 
immunity have a high incidence of malignancy 
of lymphoid or other tissues [19.20, 371. 
An increased frequency of neoplasms has also 
been found in a variety of II auto-immune" 
disorders [20]. Iatrogenic alteration of the host's 
immune apparatus also appears to have caused 
an increased incidence of neoplasia [331. 
50 far the predominant tumor types encountered 
in renal homograft recipients have been lym-
phomas, although there have been reports of a 
variety of other tumors which appeared at 
varying intervals after transplantation. These 
include an ovarian dysgerminoma [20], a carci-
noma of the cervix [28], a squamous cell carci-
noma of the ear [331, and two cases of ana-
plastic carcinoma [23, 471. 
In the present series there is a strong likelihood 
that the neoplasms began de novo at some time 
after the transplantation. Only in Case 1 was 
there any suggestion that the tumor might have 
antedated the transplant operation. In 4 cases 
the kidneys were obtained from related living 
donors who remained in good health for years 
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after their nephrectomies [331. In a further four 
cases the kidneys were obtained from cadavers 
who had no evidence of neoplasia. Although 
the donor of Case 5 had a medulloblastoma this 
tumor has little propensity to spread outside the 
central nervous system [43] and, further, it has 
no known relationship to reticulum cell sar-
coma. 
A number of the conditions present in the 
human recipients of renal homografts herein 
reported have been shown in experimental ani-
mals to be capable of inducing or influencing 
oncogenesis under the appropriate circum-
stances. Each of the main immunosuppressive 
agents, azathioprine [12, 13], prednisone [1, 2. 8, 
9, 46] and ALG [4-7, 10, 15, 16, 22] has been shown 
in animals either to (a) increase a normally low 
incidence of spontaneous, virus-induced, or 
chemically-initiated tumors; (b) to facilitate the 
ease with which malignant cells can be trans-
planted; or (c) to accelerate metastatic growth. 
In addition, thymectomy [4, 15, 21, 26, 27, 30] or 
splenectomy [3] have a similar but less certain 
effect. 
In the clinical situation, the relative contribu-
tion of any single factor is impossible to assess. 
All 9 of the patients received immunosuppres-
sive therapy with azathioprine and prednisone, 
4 received heterologous ALG, 3 underwent 
splenectomy and one had a thymectomy. Beside 
therapy with azathioprine and prednisone, the 
common feature in all cases was the continuous 
presence of antigen in the form of a homograft. 
All the patients had problems with rejection of 
varying severity and received increased im-
munosuppressive therapy to control this re-
action. The development of reticulum cell sar-
coma at the site of an ALG injection in Case 5 
is of particular interest in view of the experi-
mental work of ALLISON and LAW [4] who in-
jected mice with leukemogenic virus and ALS 
and found a remarkably high incidence of re-
ticulum cell sarcoma in the subcutaneous tis-
sues at the site of AL5 injection. 
There has been increasing acceptance of the 
concept that the immunologic system provides 
a "surveillance" function [11, 20, 25, 35] by which 
mutant neoplastic cells are identified and either 
eliminated or restricted in their growth poten-
tia!. This point of view has been strongly sup-
ported by the ease with which neoplasms have 
been accidentally transplanted from cadaveric 
renal donors who died of cancer [24] and by the 
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subsequent disappearance of a transplanted 
malignant growth in at least one case after 
immunosuppression had been discontinued [44]. 
However, the foregoing sequence of events does 
not explain the peculiar predisposition to the 
development of lympho-reticular tumors. An 
additional factor was suggested in our reports 
[33, 39] to explain this high incidence. The possi-
bility was raised that the chronic stimulation of 
the host reticulo-endothelial system by antigens 
of the homograft was responsible for the nature 
of the malignancies. The role of antigenic 
stimulation in increasing the incidence of ex-
perimental lymphomas has been well estab-
lished [14, 29, 36, 41]. 
Further experience will be required to de-
termine the frequency with which neoplastic 
growth will be a complication of clinical organ 
transplantation. At the moment, it appears that 
the incidence will be low enough so that the 
usefulness of such procedures will not be 
vitiated. In the meanwhile, it is important to be 
alert to this diagnostic possibility since only in 
this way can effective therapy be instituted as 
was accomplished in Case 3 and possibly in 
Case 5. 
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Further knowledge about the general effect of 
transplantation and immunosuppression on 
tumor growth will have an important bearing 
on the advisability of organ replacement for 
the treatment of primary malignancies of vital 
structures such as the kidney, liver and lung. 
There is already some evidence that such thera-
peutic efforts may not be as effective as might 
be hoped [40]. WILLIAMS et al. [42] performed 
renal homotransplantation in a child 6 months 
after excision of a Wilm's tumor. Sixteen 
months after transplantation, at a time when a 
cure of this kind of neoplasm would usually 
have been assured under normal conditions, 
metastases became apparent leading to death 
within a few weeks. In our series of orthotopic 
liver transplantations for hepatoma, there have 
been 4 long-term survivors. Three of these died 
of carcinomatosis 6 months, 11 months and 
13 months respectively post-transplantation. 
One is alive 13 months since a first liver trans-
plant and 2 weeks since a second liver was in-
serted to replace the first which had undergone 
chronic rejection. At the second operation the 
diaphragm and retroperitoneum contained re-
current tumor. 
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